Last week was the birth of a new UK-based bioelectronics company, Galvani Bioelectronics. The most interesting detail around Galvani is its parent companies, Verily (formerly known as Google Life Sciences) and GlaxoSmithKline. Galvani is funded by more than $700 million, which will be applied towards implants for the treatment of chronic conditions. The implants are miniature and comparable to the size of a grain of rice, and will be attached to individual nerves to treat multiple conditions including arthritis, diabetes and asthma. The change in the electrical signals in the nervous system, imposed by chronic conditions, causes a number of difficulties in the treatment of patients and impacts the quality of life of individuals. The goal of bioelectronics is partially to correct these changes.
Galvani Bioelectronics is looking to have treatments up for regulatory approval by 2023. Currently, the company employs 30 people with backgrounds in science, engineering and medicine.
For questions or inquiries, please contact Roeen Roashan, Roeen.Roashan@ihsmarkit.com.